Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 15/20 | 0.52 |
| ▸ | F2 | P00734 | 6/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.49 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.45 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6556825 | 0.99 | F10 (0.51) | F10F2ROCK2ROCK1KLKB1 | |
| SCHEMBL2997517 | 0.84 | F10 (0.45) | F10F2KLKB1PRSS1 | |
| Hydrochloric Acid SCHEMBL6554962 | 0.83 | F10 (0.44) | F10F2KLKB1PRSS1 | |
| Hydrochloric Acid SCHEMBL5094237 | 0.82 | F10 (0.43) | F10F2KLKB1PRSS1 | |
| Hydrochloric Acid SCHEMBL6556585 | 0.81 | F10 (0.44) | F10F2PRSS1 | |
| SCHEMBL6343546 | 0.80 | F10 (0.55) | F10F2PRSS1 | |
| Hydrochloric Acid SCHEMBL5091270 | 0.79 | F10 (0.54) | F10F2PRSS1 | |
| SCHEMBL7561787 | 0.78 | F10 (0.52) | F10F2PRSS1 | |
| SCHEMBL7561266 | 0.78 | F10 (0.50) | F10F2PRSS1 | |
| SCHEMBL7560669 | 0.77 | F10 (0.56) | F10F2PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1390357-A2 | ANTI-THROMBOTIC COMPOUNDS, PRODUCTION AND USE THEREOF AS MEDICAMENTS | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2004-02-25 | — | — | EP | claimed |
| US-20020151534-A1 | Antithrombotic compounds | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-10-17 | — | — | US | claimed |
| WO-2002062778-A2 | ANTI-THROMBOTIC COMPOUNDS, PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-08-15 | — | — | WO | claimed |
| EP-1390357-A2 | ANTI-THROMBOTIC COMPOUNDS, PRODUCTION AND USE THEREOF AS MEDICAMENTS | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2004-02-25 | — | — | EP | disclosed |
| US-20020151534-A1 | Antithrombotic compounds | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-10-17 | — | — | US | disclosed |
| WO-2002062778-A2 | ANTI-THROMBOTIC COMPOUNDS, PRODUCTION AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151534-A1 | Antithrombotic compounds | SERPINC1, PF4, F2 | F10 35/4885F2 3/4885ROCK2 2609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.